DOCS.L

Dr. Martens plc
Dr. Martens PLC - AGM Trading Update
11th July 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 9383V
Dr. Martens PLC
11 July 2024
 

11 July 2024

Dr. Martens plc - AGM Trading Update

 

Today, Dr. Martens plc will hold its annual general meeting at 09.30 at the Holiday Inn London, Camden Lock, 30 Jamestown Road, London.

Trading since the start of this financial year has been in line with expectations and our guidance for FY25 remains unchanged. As always, Q1 is the smallest period of our financial year, representing the end of the Spring/Summer season. As communicated in our recent FY24 results, the current financial year will be very second-half weighted, particularly from a profit perspective.  

The upcoming Autumn/Winter 24 season remains a key focus and detailed trading plans, as discussed in our recent FY24 results, are being implemented. We continue to target positive DTC growth in the USA in H2. Work on our cost action plan is ongoing and we will provide a detailed update at our first half results in November. 

 

 

Enquiries

 

Investors and analysts                                                                       

Bethany Barnes, Director of Investor Relations                                                               +44 7825 187465

                                                                                                                                                                bethany.barnes@drmartens.com

Beth Callum, Investor Relations Manager                                                                        beth.callum@drmartens.com

 

Press                                                                                                                                                    

Gill Hammond, Director of Communications                                                                   +44 7384 214248

 

H/Advisors Maitland                                                                                                          +44 20 7379 5151

Katharine Spence                                                                                                                +44 7384 535739

 

 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DMs" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. 

 

The Company listed successfully on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSFDFMSELSEDW]]>
TwitterFacebookLinkedIn